NYSE:NVO

Novo Nordisk A/S Stock Forecast, Price & News

$69.53

-0.08 (-0.11 %)

(As of 03/8/2021 12:57 PM ET)

Add

Compare

Today's Range

$68.92

Now: $69.53▼

$69.78

50-Day Range

$69.22

MA: $72.36▼

$75.82

52-Week Range

$49.24

Now: $69.53▼

$75.86

Volume29,861 shs

Average Volume1.10 million shs

Market Capitalization$163.73 billion

P/E Ratio26.14

Dividend Yield1.06%

Beta0.46

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headlines

Does Eli Lilly Have a New Blockbuster Weight Loss Drug?
March 8, 2021 | finance.yahoo.com

Trading in Novo Nordisk shares by board members, executives and associated persons on 15 February 2021
February 16, 2021 | finance.yahoo.com

Trading in Novo Nordisk shares by board members, executives and associated persons on 11-12 February 2021
February 12, 2021 | finance.yahoo.com

Diabetes drug hailed as a breakthrough for weight loss
February 11, 2021 | finance.yahoo.com

Novo Nordisk CEO on 7% sales growth in 2020, healthcare outlook
February 10, 2021 | finance.yahoo.com

Trading in Novo Nordisk shares by board members, executives and associated persons on 8 February 2021
February 10, 2021 | finance.yahoo.com

Trading in Novo Nordisk shares by board members, executives and associated persons on 3-4 February 2021
February 5, 2021 | finance.yahoo.com

Novo Nordisk A/S (NVO) Q4 2020 Earnings Call Transcript
February 3, 2021 | finance.yahoo.com

Novo Nordisk A/S to Host Earnings Call
February 3, 2021 | finance.yahoo.com

Novo Nordisk A/S: Novo Nordisk's net profit increased by 8% in 2020
February 3, 2021 | finanznachrichten.de

Novo Nordisk FY20 Results Rise; Plans Dividend, DKK 17 Bln Share Buy Back; Sees Growth In FY21
February 3, 2021 | nasdaq.com

Novo Nordisk's net profit increased by 8% in 2020
February 3, 2021 | finance.yahoo.com

Diabetes drugmaker Novo Nordisk upbeat on 2021, sees Biden boost
February 3, 2021 | finance.yahoo.com

Novo Nordisk A/S: Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
January 20, 2021 | finanznachrichten.de

Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
January 20, 2021 | finance.yahoo.com

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
January 14, 2021 | seekingalpha.com

Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com
January 4, 2021 | finance.yahoo.com

Novo Nordisk files for EU regulatory approval of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
December 29, 2020 | finance.yahoo.com

Novo Nordisk (NVO) Files for Semaglutide Label Expansion in EU
December 21, 2020 | finance.yahoo.com

Is NVO A Good Stock To Buy?
December 19, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:NVO

Previous Symbol

CUSIPN/A

CIK353278

Webwww.novonordisk.com

Phone45-4444-8888

Employees44,326

Year Founded1923

Debt

Debt-to-Equity Ratio0.04

Current Ratio1.04

Quick Ratio0.78

Price-To-Earnings

Trailing P/E Ratio26.14

Forward P/E Ratio25.01

P/E Growth2.21

Sales & Book Value

Annual Sales$18.30 billion

Price / Sales8.95

Cash Flow$2.77 per share

Price / Cash Flow25.10

Book Value$3.65 per share

Price / Book19.05

Profitability

EPS (Most Recent Fiscal Year)$2.46

Net Income$5.84 billion

Net Margins32.65%

Return on Equity71.46%

Return on Assets31.34%

Miscellaneous

Outstanding Shares2,354,800,000

Market Cap$163.73 billion

Next Earnings Date5/5/2021 (Estimated)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.34 out of 5 stars

Medical Sector

715th out of 1,968 stocks

Pharmaceutical Preparations Industry

345th out of 771 stocks

1.1 Analyst's Opinion

Consensus Rating
Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 3 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $72.00, Novo Nordisk A/S has a forecasted upside of 3.4% from its current price of $69.64.
Amount of Analyst Coverage
Novo Nordisk A/S has only been the subject of 4 research reports in the past 90 days.

2.1 Community Rank

Outperform Votes
Novo Nordisk A/S has received 349 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Novo Nordisk A/S has received 463 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Novo Nordisk A/S has received 57.02% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote “Outperform” if you believe NVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

1.7 Dividend Strength

Dividend Yield
Novo Nordisk A/S has a dividend yield of 1.06%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novo Nordisk A/S has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.
Percentage Held by Institutions
Only 5.91% of the stock of Novo Nordisk A/S is held by institutions.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Novo Nordisk A/S are expected to grow by 6.47% in the coming year, from $2.78 to $2.96 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novo Nordisk A/S is 26.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 31.19.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novo Nordisk A/S is 26.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 38.07.
Price to Earnings Growth Ratio
Novo Nordisk A/S has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novo Nordisk A/S has a P/B Ratio of 19.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$69.53

-0.08 (-0.11 %)

(As of 03/8/2021 12:57 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

What stocks does MarketBeat like better than Novo Nordisk A/S?

Wall Street analysts have given Novo Nordisk A/S a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novo Nordisk A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Novo Nordisk A/S.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Tuesday, February, 2nd. The company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $3.41. Novo Nordisk A/S had a net margin of 32.65% and a trailing twelve-month return on equity of 71.46%.
View Novo Nordisk A/S's earnings history.

How has Novo Nordisk A/S's stock price been impacted by COVID-19?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVO stock has increased by 20.0% and is now trading at $69.45.
View which stocks have been most impacted by COVID-19.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Tuesday, February 23rd. Stockholders of record on Monday, March 29th will be paid a dividend of $0.9494 per share on Wednesday, April 7th. This represents a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, March 26th. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.78.
View Novo Nordisk A/S's dividend history.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.74 per share and currently has a dividend yield of 1.06%. Novo Nordisk A/S does not yet have a strock track record of dividend growth. The dividend payout ratio of Novo Nordisk A/S is 30.08%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 25.00% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2021 Pre-Market earnings guidance on Wednesday, February, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $21.354-22.167 billion, compared to the consensus revenue estimate of $21.76 billion.

What price target have analysts set for NVO?

10 brokerages have issued 1 year target prices for Novo Nordisk A/S's stock. Their forecasts range from $72.00 to $72.00. On average, they expect Novo Nordisk A/S's stock price to reach $72.00 in the next twelve months. This suggests a possible upside of 3.7% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view top-rated stocks among Wall Street analysts.

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:

Mr. Lars Fruergaard JÃ¸rgensen, Pres, CEO & Member of Management Board (Age 55) (LinkedIn Profile)
Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 50) (LinkedIn Profile)
Dr. Mads Krogsgaard Thomsen, Exec. VP, Chief Scientific Officer, Head of R&D and Member of the Management Board (Age 61) (LinkedIn Profile)
Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 51) (LinkedIn Profile)
Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 49) (LinkedIn Profile)
Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 48) (LinkedIn Profile)
Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 51) (LinkedIn Profile)
Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 55) (LinkedIn Profile)
Mr. Ludovic Helfgott, Exec. VP, Head of Biopharm & Member of Management Board (Age 47) (LinkedIn Profile)
Mr. Peter Hugreffe Ankersen, Head of Investor Relations & Corp. VP

What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Novo Nordisk A/S's key competitors?

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche (RHHBY), Abbott Laboratories (ABT), Eli Lilly and (LLY), Novartis (NVS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), CSL (CSLLY), GlaxoSmithKline (GSK), Zoetis (ZTS) and Bayer Aktiengesellschaft (BAYRY).
View all of NVO's competitors.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.14%), Fisher Asset Management LLC (0.67%), Folketrygdfondet (0.24%), Fayez Sarofim & Co (0.21%), Everett Harris & Co. CA (0.14%) and Clearbridge Investments LLC (0.11%).
View institutional ownership trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Eaton Vance Management, Eaton Vance Management, Jennison Associates LLC, Credit Suisse AG, BlackRock Inc., Alliancebernstein L.P., and Calamos Advisors LLC.
View insider buying and selling activity for Novo Nordisk A/S or view top insider-selling stocks.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Amundi Pioneer Asset Management Inc., Clearbridge Investments LLC, Folketrygdfondet, Fisher Asset Management LLC, Aperio Group LLC, Creative Planning, and Penbrook Management LLC.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $69.45.

How much money does Novo Nordisk A/S make?

Novo Nordisk A/S has a market capitalization of $163.54 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 44,326 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

Where are Novo Nordisk A/S's headquarters?

Novo Nordisk A/S is headquartered at Novo Alle, Bagsvaerd G7, 2880.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here